Are antiphospholipid antibodies associated with thrombotic complications in critically ill COVID-19 patients?

Thromb Res. 2020 Nov:195:74-76. doi: 10.1016/j.thromres.2020.07.016. Epub 2020 Jul 8.

¹ Laboratory of Hematology, Lariboisière Hospital, Paris University, Paris, France; INSERM UMRS 1140, Paris University, Paris, France. Electronic address: virginie.siguret@aphp.fr.
² Department of Medical and Toxicological Critical Care, Lariboisière Hospital, Paris University, Paris, France; INSERM UMRS 1144, Paris University, Paris, France.
³ Laboratory of Hematology, Lariboisière Hospital, Paris University, Paris, France; INSERM UMRS 1140, Paris University, Paris, France.
⁴ Laboratory of Hematology, Lariboisière Hospital, Paris University, Paris, France; EA 3518, Paris University, Paris, France.
⁵ Department of Anesthesiology and Critical Care, Lariboisière Hospital, Paris University, Paris, France.

Abstract

•
The prevalence of aPL antibodies is poorly documented in ICU COVID-19 patients.
•
LA based on dRVVT system was positive in 85% of critically ill COVID-19 patients.
•
LA was not associated with thrombotic complications.
•
The prevalence of elevated anticardiolipin IgG/M/anti-beta2-GPI IgG was of 12%.

Keywords: Anti-β2-glycoprotein-I; Anticardiolipin; COVID-19; Lupus anticoagulant; Thrombosis.